Geroscience & senolytics

01Overview and value chain#

Markers EC: European Innovation Partnership on Active and Healthy Ageing | OECD: bio-pharma | Regulator: FDA (US), EMA (EU), NMPA (CN)

Geroscience targets the shared molecular and cellular hallmarks of aging that underlie most chronic age-related diseases, rather than treating each disease separately. Its most clinically advanced arm is senolytics — small molecules or biologics that selectively clear senescent “zombie” cells, which stop dividing but resist apoptosis and instead secrete a toxic inflammatory cocktail (the senescence-associated secretory phenotype, or SASP) that drives chronic low-grade inflammation and drags neighboring healthy cells into senescence. Unity Biotechnology’s lead senolytic, UBX1325, a Bcl-xL inhibitor delivered locally into the eye, has produced 36-week clinical results and a publication in NEJM Evidence supporting long-term vision improvement in diabetic macular edema. In a parallel clinical program, Mayo Clinic researchers ran a Phase 1 trial of the senolytic combination dasatinib plus quercetin (D+Q) in diabetic kidney disease, directly measuring a reduction in senescent-cell markers in treated patients. Rubedo Life Sciences has reported positive preliminary Phase 1 results for RLS-1496, a topical GPX4-modulating senolytic for plaque psoriasis, atopic dermatitis and skin aging, identified through its AI-driven ALEMBIC platform. Altos Labs, launched around 2022 with roughly $3 billion in funding, is pursuing a parallel strategy — partial cellular reprogramming to reverse a cell’s biological age without erasing its identity — rather than clearing senescent cells outright.

The key directions of geroscience and senolytics are:

1. Senolytics: small molecules or peptides that selectively trigger apoptosis in senescent cells by disabling their survival pathways (SCAP networks), such as Bcl-2/Bcl-xL inhibition or FOXO4-p53 disruption.
2. Senomorphics: compounds — such as mTOR inhibitors (rapamycin analogs) and metformin — that don’t kill senescent cells but suppress their toxic SASP secretion.
3. Cellular rejuvenation: partial epigenetic reprogramming with Yamanaka factors to roll back a cell’s biological age while preserving its cell-type identity.
4. Senescence biomarking: biomarker platforms (SA-β-gal activity, single-cell RNA-seq, SASP cytokine panels) used to identify senescent cells and measure how effectively a therapy clears them.

Sectoral value chain#

[Aging-Marker Identification] ──> [Senolytic Candidate Screening] ──> [Preclinical Testing (In Vivo)]
                  │                                 │                              │
        (SASP profiling, biomarkers)        (Compound libraries, HTS)    (Aged mouse models)
                                                                                    │
[Clinical Release (GMP)] <─── [Preclinical Synthesis & Purification (HPLC)] <──────┘

Value chain levels#

Cross-cutting technologies of the sector:

• SA-β-gal detection: the classic senescent-cell biomarker — enlarged lysosomes in senescent cells sharply raise beta-galactosidase activity at pH 6.0, letting researchers quantify how well a therapy clears zombie cells from tissue.
• Bcl-2/Bcl-xL inhibition: drugs (e.g., navitoclax, UBX1325) that block the anti-apoptotic Bcl-2-family proteins senescent cells rely on for survival, pushing the cell into programmed apoptosis.
• FOXO4-DRI peptide design: a synthetic peptide that disrupts the FOXO4-p53 interaction in senescent cells, releasing p53 to trigger apoptosis while sparing healthy dividing cells.

02US#

The US is the epicenter of the global longevity industry, combining a deep venture-capital ecosystem with pioneering academic geroscience centers.

senolytic clinical trials, cellular reprogramming megaprojects, academic senolytic discovery#

• Unity Biotechnology: its lead senolytic, UBX1325 (a Bcl-xL inhibitor), has produced 36-week clinical results and a NEJM Evidence publication supporting long-term vision improvement in diabetic macular edema and retinal disease.
• Rubedo Life Sciences: develops selective senolytics using its AI-driven ALEMBIC platform; its lead candidate RLS-1496, a topical GPX4 modulator, reported positive preliminary Phase 1 results in plaque psoriasis, atopic dermatitis and skin aging.
• Altos Labs: launched around 2022 with roughly $3 billion in funding, pursuing partial cellular reprogramming for cellular rejuvenation rather than senescent-cell clearance.
• Mayo Clinic: ran a Phase 1 trial of the senolytic combination dasatinib plus quercetin (D+Q) in diabetic kidney disease, directly measuring reduced senescent-cell burden in treated patients.

03CN#

China treats geroscience as a strategic response to rapid population aging and pension-system pressure, combining domestic senolytic discovery with dominance in a key longevity-supplement supply chain.

aging research in Beijing, NAD+ precursor manufacturing, domestic senolytic compound discovery#

• Beijing research centers: the Institute of Zoology (Chinese Academy of Sciences) and Peking University are China’s leading aging-research centers, working on longevity-gene replacement approaches and natural senolytic compound discovery.
• NAD+ precursor manufacturing scale: China is the leading global producer and exporter of NAD+ coenzyme precursors such as nicotinamide mononucleotide (NMN), manufactured at large scale as a geroprotective supplement ingredient for export markets.
• Policy support: anti-aging research is incorporated into China’s national technology development programs, driving parallel investment in epigenetic-clock biological-age diagnostics.

04EU#

The EU concentrates on fundamental geroscience and peptide-based senolytic discovery, operating under an EMA framework that does not recognize aging itself as an indication.

fundamental aging-pathway research, peptide senolytic design, EMA indication-specific regulation#

• Max Planck Institute for Biology of Ageing (Cologne): a leading European academic hub studying molecular aging pathways (IIS, mTOR) in model organisms and coordinating geroprotector research across the EU.
• Cleara Biotech (Netherlands): founded in 2018, develops the FOXO4-DRI senolytic peptide, which disrupts the FOXO4-p53 interaction to selectively trigger apoptosis in senescent cells.
• EMA regulatory posture: EMA does not recognize biological aging as a standalone indication, so European senolytic developers must register their therapies against specific age-related diagnoses (e.g., idiopathic pulmonary fibrosis, osteoarthritis, sarcopenia) under existing disease codes.

05Leading companies and research institutes#

06Tech stack and innovations#

Modern geroprotector production and validation rests on the following technology stack:

1. Solid-phase peptide synthesis (SPPS):
   • Peptide senolytics like FOXO4-DRI are built stepwise on a solid resin using Fmoc-protected amino acids; substituting standard L-amino acids with mirror-image D-amino acids (retro-inverso peptides) makes them highly resistant to proteolytic degradation in blood.
2. Single-cell RNA sequencing (scRNA-seq):
   • Because senescent cells make up under roughly 1-5% of the total cell pool in aged tissue, bulk tissue sequencing can’t detect their signal; scRNA-seq profiles the RNA expression of thousands of individual cells to map specific SCAP-network and SASP-cytokine markers.
3. Ultra-high-performance liquid chromatography (UPLC-MS/MS):
   • Used to quantify SASP biomarkers (IL-6, IL-1, MCP-1 and related inflammatory proteins) in patient serum before and after senolytic therapy, assessing systemic anti-inflammatory and rejuvenating effect.

07Value chains and production pipelines#

Industrial pipeline of GMP production for a peptide-type senolytic (FOXO4-DRI)#

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Solid-phase Fmoc       │ ───> │ 2. Cleavage from resin    │
│    synthesis (D-amino     │      │    with acid (TFA)         │
│    acids)                 │      │                            │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Membrane dialysis &    │ <─── │ 3. RP-HPLC chromatography │
│    desalting (TFF)        │      │    (substance purity)      │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Buffer formulation &   │ ───> │ 6. Sterile filtration &   │
│    SA-gal potency assay   │      │    aseptic fill-finish     │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Solid-phase peptide synthesis (SPPS)

A polymeric resin support (e.g., Rink amide resin) is loaded into an automated peptide synthesizer to build the FOXO4-DRI retro-inverso peptide from D-amino acid isomers, cycling through Fmoc deprotection, activation and coupling for each residue.

Stage 2: Cleavage from the polymeric support

Once the sequence is complete, the resin is washed and treated with a trifluoroacetic acid (TFA)/water/triisopropylsilane mixture, which cleaves the peptide from the resin and removes side-chain protecting groups; the crude peptide is precipitated in cold ether and dried.

Stage 3: Preparative RP-HPLC purification

The crude peptide is dissolved and loaded onto a C18 reverse-phase HPLC column, purified by an acetonitrile gradient, and collected at target purity (typically at least 98%) by UV detection.

Stage 4: Desalting and acetate-salt conversion

The eluate is processed by tangential-flow filtration (TFF) with a low-molecular-weight-cutoff membrane, exchanging residual TFA ions for physiological acetate ions via repeated diafiltration.

Stage 5: Formulation and potency testing

The purified peptide acetate is dissolved in sterile phosphate-buffered saline; identity and purity are confirmed by high-resolution mass spectrometry, and an in-vitro potency assay confirms selective apoptosis of senescent (SA-β-gal-positive) fibroblasts without harming healthy dividing controls.

Stage 6: Sterile filtration, fill and lyophilization

The formulated solution is sterile-filtered, filled into vials in a GMP Class A aseptic zone, lyophilized, sealed, labeled and stored under refrigeration ahead of clinical use.